+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Non Hodgkin Lymphoma Therapeutics Market Size, Share & Trends Analysis Report By Cell Type (B-Cell Lymphoma and T-Cell Lymphoma), By Therapy Type (Radiation Therapy, Chemotherapy, Targeted Therapy, and Others), By Regional Outlook and Forecast, 2023 - 2030

  • PDF Icon

    Report

  • 193 Pages
  • January 2024
  • Region: Global
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5928449
The Global Non Hodgkin Lymphoma Therapeutics Market size is expected to reach $16.8 billion by 2030, rising at a market growth of 8.4% CAGR.

North America has been at the forefront of developing and implementing immunotherapies, providing new avenues for treating NHL, especially in relapsed or refractory cases. Therefore, the North America region captured $3,690.9 million revenue in the market in 2022. Non hodgkin lymphoma is more commonly diagnosed in older individuals, and the risk of NHL generally increases with age in Canada. As the senior population grows, there may be a corresponding increase in the number of NHL cases in Canada. The demand for healthcare services, including cancer diagnosis and treatment, may increase with the growing senior population in Canada.

High-dimensional flow cytometry and advanced immunophenotyping techniques enhance the characterization of lymphoma cells. Improved cell profiling contributes to accurate subtyping, aiding treatment selection and prognosis determination. Advances in cytogenetic analysis and FISH techniques enhance the detection of chromosomal abnormalities associated with specific NHL subtypes. Improved cytogenetic profiling aids in risk stratification and informs treatment decisions, contributing to personalized therapeutic strategies. Therefore, it is expanding significantly due to the growing prevalence of respiratory diseases. Additionally, increased awareness and screening programs contribute to the early detection of non-hodgkin lymphoma. Early detection allows prompt treatment, positively impacting patient outcomes and driving the demand for therapeutic options. An increase in the number of HIV/AIDS cases globally. HIV/AIDS is a known risk factor for NHL, and the rise in HIV/AIDS cases contributes to the overall incidence and therapeutic demand. Thus, rising incidence of non-hodgkin lymphoma has been a pivotal factor in driving the growth of the market.

Further, the pandemic led to disruptions in routine healthcare services, including delays in cancer screenings, diagnostic procedures, and elective treatments. Oncologists adapted treatment plans to minimize hospital visits and reduce the risk of infection for vulnerable patients. Many clinical trials were temporarily halted or delayed due to safety concerns, resource allocation, and logistical challenges. This disruption affected the progression of novel therapies through the development pipeline, potentially delaying access to innovative treatments for NHL. Disruptions in the global supply chain affected the availability of certain drugs and therapeutic agents. These innovations may lead to long-term changes in how healthcare is delivered, providing more patient-centric and flexible solutions in the future. Thus, the COVID-19 pandemic had a moderate effect on the market.

However, the high cost of novel therapies strains healthcare budgets and reimbursement systems. Healthcare systems may face challenges in allocating resources, potentially leading to delays in adopting new treatments or restrictions on their availability. Delays in reimbursement approvals may hinder the timely entry of novel therapies into the market. Manufacturers may face challenges in recovering development costs, potentially slowing down research and development initiatives. Payers and insurers may experience financial strain due to the high cost of covering novel therapies. This strain can lead to increased premiums, out-of-pocket patient costs, or reluctance from payers to cover certain therapies. Thus, the high cost of novel therapies can slow down the growth of the market.

By Therapy Type Analysis

Based on therapy type, the market is classified into chemotherapy, radiation therapy, targeted therapy, and others. In 2022, the radiation therapy segment dominated with maximum revenue share. Radiation therapy is particularly effective for localized disease, where cancer is confined to a specific area. Its precision allows for targeting cancer cells while minimizing damage to surrounding healthy tissues. Radiation therapy can be combined with other treatment modalities, such as chemotherapy or immunotherapy, to enhance the overall effectiveness of the treatment. This combination approach may lead to better outcomes for patients with non hodgkin lymphoma. Advances in radiation therapy technology, such as intensity-modulated radiation therapy (IMRT) and image-guided radiation therapy (IGRT), have improved the precision and accuracy of treatment delivery. This can result in better tumor targeting and reduced side effects.

By Cell Type Analysis

By cell type, the market is categorized into B-cell lymphoma and T-cell lymphoma. The T-cell lymphoma segment covered a considerable revenue share in the market in 2022. HDAC inhibitors, such as romidepsin and belinostat, have been approved for certain T-cell lymphomas. They work by modifying the activity of proteins involved in gene expression. T-cell lymphomas may be treated with allogeneic stem cell transplantation, where healthy stem cells from a donor are used to replace damaged or cancerous cells. This approach can offer a potential cure for some patients. Traditional chemotherapy is still a part of the treatment regimen for T-cell lymphomas. Combinations of chemotherapy agents with other targeted therapies or immunotherapies are explored to improve treatment outcomes.

By Regional Analysis

Region-wise, the market is analysed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the Asia Pacific region acquired a significant revenue share in the market. The Asia Pacific region has become increasingly involved in clinical trials and research collaborations. Telemedicine facilitates access to expert consultations, especially in remote or underserved areas, contributing to improved patient care and treatment planning in Asia Pacific. HSCT programs are evolving in the Asia Pacific region. The pharmaceutical industry is investing in research and development in the Asia Pacific region.

Recent Strategies Deployed in the Market

  • Nov-2023: AbbVie, Inc. took over ImmunoGen, a US-based biotechnology company. Through this acquisition, AbbVie, Inc. would bolster the scope of our oncology pipeline, encompassing both solid tumors and hematologic malignancies.
  • Aug-2023: Novartis AG took over Chinook Therapeutics, a clinical-stage biopharmaceutical company in Seattle, WA. Through this acquisition, Novartis AG would utilize collective resources and expertise, to advance the development of promising treatments for the well-being of patients affected by rare and severe chronic kidney diseases.
  • Jul-2023: Pfizer Inc. came into partnership with Flagship Pioneering, an American life sciences venture capital company. Through this partnership, Pfizer Inc. would utilize a distinctive innovation supply chain, aiming to expedite the development of transformative medicines efficiently.
  • Mar-2023: Pfizer Inc. took over Seagen, a US-based Biotechnology company. Through this acquisition, Pfizer Inc. would enhance its expertise in protein engineering to create advanced biologics in the next generation.
  • Aug-2022: Sanofi S.A. came into partnership with Innovent Bio, a biopharmaceutical company in China. Through this partnership, Sanofi S.A. would enhance the development of cancer treatment and bolster its market presence in China.

List of Key Companies Profiled

  • Pfizer Inc.
  • F.Hoffmann-La Roche Ltd
  • Sanofi S.A.
  • AbbVie, Inc.
  • Novartis AG
  • GlaxoSmithKline PLC
  • Johnson & Johnson (Johnson & Johnson Services, Inc.)
  • Takeda Pharmaceutical Company Limited
  • Bayer AG
  • Bristol-Myers Squibb Company

Market Report Segmentation

By Cell Type

  • B-Cell Lymphoma
  • T-Cell Lymphoma

By Therapy Type

  • Radiation Therapy
  • Chemotherapy
  • Targeted Therapy
  • Others

By Geography

  • North America
  • US
  • Canada
  • Mexico
  • Rest of North America
  • Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
  • LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Non Hodgkin Lymphoma Therapeutics Market, by Cell Type
1.4.2 Global Non Hodgkin Lymphoma Therapeutics Market, by Therapy Type
1.4.3 Global Non Hodgkin Lymphoma Therapeutics Market, by Geography
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.3 Porter Five Forces Analysis
Chapter 4. Strategies Deployed in Non Hodgkin Lymphoma Therapeutics Market.
Chapter 5. Global Non Hodgkin Lymphoma Therapeutics Market by Cell Type
5.1 Global B-Cell Lymphoma Market by Region
5.2 Global T-Cell Lymphoma Market by Region
Chapter 6. Global Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
6.1 Global Radiation Therapy Market by Region
6.2 Global Chemotherapy Market by Region
6.3 Global Targeted Therapy Market by Region
6.4 Global Others Market by Region
Chapter 7. Global Non Hodgkin Lymphoma Therapeutics Market by Region
7.1 North America Non Hodgkin Lymphoma Therapeutics Market
7.1.1 North America Non Hodgkin Lymphoma Therapeutics Market by Cell Type
7.1.1.1 North America B-Cell Lymphoma Market by Country
7.1.1.2 North America T-Cell Lymphoma Market by Country
7.1.2 North America Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
7.1.2.1 North America Radiation Therapy Market by Country
7.1.2.2 North America Chemotherapy Market by Country
7.1.2.3 North America Targeted Therapy Market by Country
7.1.2.4 North America Others Market by Country
7.1.3 North America Non Hodgkin Lymphoma Therapeutics Market by Country
7.1.3.1 US Non Hodgkin Lymphoma Therapeutics Market
7.1.3.1.1 US Non Hodgkin Lymphoma Therapeutics Market by Cell Type
7.1.3.1.2 US Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
7.1.3.2 Canada Non Hodgkin Lymphoma Therapeutics Market
7.1.3.2.1 Canada Non Hodgkin Lymphoma Therapeutics Market by Cell Type
7.1.3.2.2 Canada Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
7.1.3.3 Mexico Non Hodgkin Lymphoma Therapeutics Market
7.1.3.3.1 Mexico Non Hodgkin Lymphoma Therapeutics Market by Cell Type
7.1.3.3.2 Mexico Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
7.1.3.4 Rest of North America Non Hodgkin Lymphoma Therapeutics Market
7.1.3.4.1 Rest of North America Non Hodgkin Lymphoma Therapeutics Market by Cell Type
7.1.3.4.2 Rest of North America Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
7.2 Europe Non Hodgkin Lymphoma Therapeutics Market
7.2.1 Europe Non Hodgkin Lymphoma Therapeutics Market by Cell Type
7.2.1.1 Europe B-Cell Lymphoma Market by Country
7.2.1.2 Europe T-Cell Lymphoma Market by Country
7.2.2 Europe Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
7.2.2.1 Europe Radiation Therapy Market by Country
7.2.2.2 Europe Chemotherapy Market by Country
7.2.2.3 Europe Targeted Therapy Market by Country
7.2.2.4 Europe Others Market by Country
7.2.3 Europe Non Hodgkin Lymphoma Therapeutics Market by Country
7.2.3.1 Germany Non Hodgkin Lymphoma Therapeutics Market
7.2.3.1.1 Germany Non Hodgkin Lymphoma Therapeutics Market by Cell Type
7.2.3.1.2 Germany Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
7.2.3.2 UK Non Hodgkin Lymphoma Therapeutics Market
7.2.3.2.1 UK Non Hodgkin Lymphoma Therapeutics Market by Cell Type
7.2.3.2.2 UK Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
7.2.3.3 France Non Hodgkin Lymphoma Therapeutics Market
7.2.3.3.1 France Non Hodgkin Lymphoma Therapeutics Market by Cell Type
7.2.3.3.2 France Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
7.2.3.4 Russia Non Hodgkin Lymphoma Therapeutics Market
7.2.3.4.1 Russia Non Hodgkin Lymphoma Therapeutics Market by Cell Type
7.2.3.4.2 Russia Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
7.2.3.5 Spain Non Hodgkin Lymphoma Therapeutics Market
7.2.3.5.1 Spain Non Hodgkin Lymphoma Therapeutics Market by Cell Type
7.2.3.5.2 Spain Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
7.2.3.6 Italy Non Hodgkin Lymphoma Therapeutics Market
7.2.3.6.1 Italy Non Hodgkin Lymphoma Therapeutics Market by Cell Type
7.2.3.6.2 Italy Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
7.2.3.7 Rest of Europe Non Hodgkin Lymphoma Therapeutics Market
7.2.3.7.1 Rest of Europe Non Hodgkin Lymphoma Therapeutics Market by Cell Type
7.2.3.7.2 Rest of Europe Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
7.3 Asia Pacific Non Hodgkin Lymphoma Therapeutics Market
7.3.1 Asia Pacific Non Hodgkin Lymphoma Therapeutics Market by Cell Type
7.3.1.1 Asia Pacific B-Cell Lymphoma Market by Country
7.3.1.2 Asia Pacific T-Cell Lymphoma Market by Country
7.3.2 Asia Pacific Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
7.3.2.1 Asia Pacific Radiation Therapy Market by Country
7.3.2.2 Asia Pacific Chemotherapy Market by Country
7.3.2.3 Asia Pacific Targeted Therapy Market by Country
7.3.2.4 Asia Pacific Others Market by Country
7.3.3 Asia Pacific Non Hodgkin Lymphoma Therapeutics Market by Country
7.3.3.1 China Non Hodgkin Lymphoma Therapeutics Market
7.3.3.1.1 China Non Hodgkin Lymphoma Therapeutics Market by Cell Type
7.3.3.1.2 China Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
7.3.3.2 Japan Non Hodgkin Lymphoma Therapeutics Market
7.3.3.2.1 Japan Non Hodgkin Lymphoma Therapeutics Market by Cell Type
7.3.3.2.2 Japan Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
7.3.3.3 India Non Hodgkin Lymphoma Therapeutics Market
7.3.3.3.1 India Non Hodgkin Lymphoma Therapeutics Market by Cell Type
7.3.3.3.2 India Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
7.3.3.4 South Korea Non Hodgkin Lymphoma Therapeutics Market
7.3.3.4.1 South Korea Non Hodgkin Lymphoma Therapeutics Market by Cell Type
7.3.3.4.2 South Korea Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
7.3.3.5 Singapore Non Hodgkin Lymphoma Therapeutics Market
7.3.3.5.1 Singapore Non Hodgkin Lymphoma Therapeutics Market by Cell Type
7.3.3.5.2 Singapore Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
7.3.3.6 Malaysia Non Hodgkin Lymphoma Therapeutics Market
7.3.3.6.1 Malaysia Non Hodgkin Lymphoma Therapeutics Market by Cell Type
7.3.3.6.2 Malaysia Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
7.3.3.7 Rest of Asia Pacific Non Hodgkin Lymphoma Therapeutics Market
7.3.3.7.1 Rest of Asia Pacific Non Hodgkin Lymphoma Therapeutics Market by Cell Type
7.3.3.7.2 Rest of Asia Pacific Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
7.4 LAMEA Non Hodgkin Lymphoma Therapeutics Market
7.4.1 LAMEA Non Hodgkin Lymphoma Therapeutics Market by Cell Type
7.4.1.1 LAMEA B-Cell Lymphoma Market by Country
7.4.1.2 LAMEA T-Cell Lymphoma Market by Country
7.4.2 LAMEA Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
7.4.2.1 LAMEA Radiation Therapy Market by Country
7.4.2.2 LAMEA Chemotherapy Market by Country
7.4.2.3 LAMEA Targeted Therapy Market by Country
7.4.2.4 LAMEA Others Market by Country
7.4.3 LAMEA Non Hodgkin Lymphoma Therapeutics Market by Country
7.4.3.1 Brazil Non Hodgkin Lymphoma Therapeutics Market
7.4.3.1.1 Brazil Non Hodgkin Lymphoma Therapeutics Market by Cell Type
7.4.3.1.2 Brazil Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
7.4.3.2 Argentina Non Hodgkin Lymphoma Therapeutics Market
7.4.3.2.1 Argentina Non Hodgkin Lymphoma Therapeutics Market by Cell Type
7.4.3.2.2 Argentina Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
7.4.3.3 UAE Non Hodgkin Lymphoma Therapeutics Market
7.4.3.3.1 UAE Non Hodgkin Lymphoma Therapeutics Market by Cell Type
7.4.3.3.2 UAE Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
7.4.3.4 Saudi Arabia Non Hodgkin Lymphoma Therapeutics Market
7.4.3.4.1 Saudi Arabia Non Hodgkin Lymphoma Therapeutics Market by Cell Type
7.4.3.4.2 Saudi Arabia Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
7.4.3.5 South Africa Non Hodgkin Lymphoma Therapeutics Market
7.4.3.5.1 South Africa Non Hodgkin Lymphoma Therapeutics Market by Cell Type
7.4.3.5.2 South Africa Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
7.4.3.6 Nigeria Non Hodgkin Lymphoma Therapeutics Market
7.4.3.6.1 Nigeria Non Hodgkin Lymphoma Therapeutics Market by Cell Type
7.4.3.6.2 Nigeria Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
7.4.3.7 Rest of LAMEA Non Hodgkin Lymphoma Therapeutics Market
7.4.3.7.1 Rest of LAMEA Non Hodgkin Lymphoma Therapeutics Market by Cell Type
7.4.3.7.2 Rest of LAMEA Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
Chapter 8. Company Profiles
8.1 Pfizer, Inc.
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Regional & Segmental Analysis
8.1.4 Research & Development Expense
8.1.5 Recent strategies and developments:
8.1.5.1 Partnerships, Collaborations, and Agreements:
8.1.5.2 Product Launches and Product Expansions:
8.1.5.3 Acquisition and Mergers:
8.1.6 SWOT Analysis
8.2 F. Hoffmann-La Roche Ltd.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental and Regional Analysis
8.2.4 Research & Development Expense
8.2.5 SWOT Analysis
8.3 Sanofi S.A.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental and Regional Analysis
8.3.4 Research & Development Expense
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.3.6 SWOT Analysis
8.4 AbbVie, Inc.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Regional Analysis
8.4.4 Research & Development Expense
8.4.5 Recent strategies and developments:
8.4.5.1 Acquisition and Mergers:
8.4.6 SWOT Analysis
8.5 Novartis AG
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expense
8.5.5 Recent strategies and developments:
8.5.5.1 Acquisition and Mergers:
8.5.6 SWOT Analysis
8.6 GlaxoSmithKline PLC
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Regional Analysis
8.6.4 Research & Development Expense
8.6.5 Recent strategies and developments:
8.6.5.1 Partnerships, Collaborations, and Agreements:
8.6.6 SWOT Analysis
8.7 Johnson & Johnson (Johnson & Johnson Services, Inc.)
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental &Regional Analysis
8.7.4 SWOT Analysis
8.8 Takeda Pharmaceutical Company Limited
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Regional Analysis
8.8.4 Research & Development Expense
8.8.5 SWOT Analysis
8.9 Bayer AG
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Segmental and Regional Analysis
8.9.4 Research & Development Expense
8.9.5 SWOT Analysis
8.10. Bristol-Myers Squibb Company
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Regional Analysis
8.10.4 Research & Development Expenses
8.10.5 SWOT Analysis
Chapter 9. Winning Imperatives for Non Hodgkin Lymphoma Therapeutics Market

Companies Mentioned

  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd
  • Sanofi S.A.
  • AbbVie, Inc.
  • Novartis AG
  • GlaxoSmithKline PLC
  • Johnson & Johnson (Johnson & Johnson Services, Inc.)
  • Takeda Pharmaceutical Company Limited
  • Bayer AG
  • Bristol-Myers Squibb Company

Methodology

Loading
LOADING...